Indivior flags delay to FDA review of Sublocade label change.
Indivior announced a delay in the US Food and Drug Administration's (FDA) final review of proposed label changes for its ‘Sublocade’, or buprenorphine extended-release, injection on Wednesday.
Indivior
12 February 2025 08:34:06
Source: Sharecast
The company was expecting a decision by 7 February, as per the Prescription Drug User Fee Act (PDUFA) timeline.
It said on Wednesday that the FDA informed the company on 11 February that there were no outstanding issues following acceptance of the proposed label, which includes a rapid initiation protocol and alternative injection sites.
However, the final review process has been delayed.
The company did not provide a revised timeline for approval but said it would issue further updates as appropriate.
At 0813 GMT, shares in Indivior were up 6.47% at 814.5p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
